Formula30A is dedicated to furthering cannabinoid research and education for the benefit of the medical community and the patients under their care. On August 1st, 2022, the Formula30A Medical Advisory Board began conducting the first IRB-approved study in the United States using full spectrum CBG (Cannabigerol) with healthy human adults.

Conducted across 7 clinics in the US and Puerto Rico, this study will examine the physiological and psychological effects of consumption of one 50mg Formula30A CBG Capsule daily over the course of 8 weeks, followed by a 4-week washout period.

​

Participation in this study is voluntary and limited to registrants that have completed the Informed Consent form process at an in-person clinic visit with their participating healthcare provider. If you have not yet signed an Informed Consent form, please do not attempt to register for this program.

 

To enroll in the study, invited participants should schedule an appointment with a healthcare provider who is an approved study Principle Investigator to review the study protocols and complete the Informed Consent process.